- Home
- CHCT vs DNTH Comparison
CHCT vs DNTH Comparison
Compare CHCT & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- DNTH
- Stock Information
- Founded
- CHCT 2014
- DNTH 2015
- Country
- CHCT United States
- DNTH United States
- Employees
- CHCT N/A
- DNTH N/A
- Industry
- CHCT Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- CHCT Real Estate
- DNTH Health Care
- Exchange
- CHCT Nasdaq
- DNTH Nasdaq
- Market Cap
- CHCT 559.3M
- DNTH 670.7M
- IPO Year
- CHCT 2015
- DNTH N/A
- Fundamental
- Price
- CHCT $20.00
- DNTH $22.29
- Analyst Decision
- CHCT Buy
- DNTH Strong Buy
- Analyst Count
- CHCT 4
- DNTH 9
- Target Price
- CHCT $21.25
- DNTH $46.43
- AVG Volume (30 Days)
- CHCT 186.8K
- DNTH 245.5K
- Earning Date
- CHCT 02-18-2025
- DNTH 03-20-2025
- Dividend Yield
- CHCT 9.19%
- DNTH N/A
- EPS Growth
- CHCT N/A
- DNTH N/A
- EPS
- CHCT N/A
- DNTH N/A
- Revenue
- CHCT $115,612,000.00
- DNTH $5,366,000.00
- Revenue This Year
- CHCT N/A
- DNTH $100.14
- Revenue Next Year
- CHCT $7.55
- DNTH N/A
- P/E Ratio
- CHCT N/A
- DNTH N/A
- Revenue Growth
- CHCT 6.00
- DNTH 51.41
- 52 Week Low
- CHCT $15.06
- DNTH $18.35
- 52 Week High
- CHCT $28.10
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- CHCT 49.80
- DNTH 49.77
- Support Level
- CHCT $19.39
- DNTH $21.28
- Resistance Level
- CHCT $20.87
- DNTH $23.28
- Average True Range (ATR)
- CHCT 0.52
- DNTH 1.75
- MACD
- CHCT -0.06
- DNTH 0.17
- Stochastic Oscillator
- CHCT 20.56
- DNTH 79.92
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.